Hoth Therapeutics Inc (HOTH) - Total Assets
Based on the latest financial reports, Hoth Therapeutics Inc (HOTH) holds total assets worth $5.59 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See HOTH net asset quality index to measure how much of total assets are equity-financed.
Hoth Therapeutics Inc - Total Assets Trend (2017–2025)
This chart illustrates how Hoth Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Explore Hoth Therapeutics Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.
Hoth Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Hoth Therapeutics Inc's total assets of $5.59 Million consist of 90.3% current assets and 9.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 82.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Hoth Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Hoth Therapeutics Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hoth Therapeutics Inc's current assets represent 90.3% of total assets in 2025, a decrease from 99.7% in 2017.
- Cash Position: Cash and equivalents constituted 82.2% of total assets in 2025, down from 99.7% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Hoth Therapeutics Inc Competitors by Total Assets
Key competitors of Hoth Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Hoth Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.39 | 15.08 | 14.41 |
| Quick Ratio | 3.39 | 15.08 | 14.41 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.43 Million | $11.48 Million | $16.35 Million |
Hoth Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Hoth Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.63 |
| Latest Market Cap to Assets Ratio | 2.80 |
| Asset Growth Rate (YoY) | -1.4% |
| Total Assets | $7.60 Million |
| Market Capitalization | $21.33 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Hoth Therapeutics Inc's assets at a significant premium (2.80x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Hoth Therapeutics Inc's assets decreased by 1.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Hoth Therapeutics Inc (2017–2025)
The table below shows the annual total assets of Hoth Therapeutics Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $7.60 Million | -1.42% |
| 2024-12-31 | $7.71 Million | -24.70% |
| 2023-12-31 | $10.24 Million | +51.54% |
| 2022-12-31 | $6.76 Million | -38.47% |
| 2021-12-31 | $10.99 Million | +109.53% |
| 2020-12-31 | $5.24 Million | +84.86% |
| 2019-12-31 | $2.84 Million | +462.82% |
| 2018-12-31 | $503.92K | -59.16% |
| 2017-12-31 | $1.23 Million | -- |
About Hoth Therapeutics Inc
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs in the United States. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to … Read more